Crucially, the pan-caspase inhibitor z-VAD-fmk and the caspase-3 inhibitor z-DEVD-fmk significantly mitigated the reduction in P1 glioma cell viability and cell death induced by shORC6-s1, as demonstrated by CCK-8 (Fig. 5I) and Trypan blue staining (Fig. 5J) assays, respectively. This evidence concerns the gene CASP3 and central nervous system cancer.